Clinical Trial Transparency & Disclosures

Trusted support to meet the daily demands of pharmaceutical industry transparency requirements

The MMS team members were brilliant at performing redactions across our project!
Regulatory Operations Manager
Top 5 Pharmaceutical Sponsor

MMS provides end-to-end transparency services support, with our deep knowledge in transparency laws, global regulations, and pharmaceutical industry requirements. Sponsors like you trust MMS to alleviate the day-to-day activity burden of transparency by facilitating cross-functional engagement, ensuring legal and regulatory compliance, and enabling responsible data sharing.

We do all this while maintaining patient privacy and the protection of company confidential information.

View the depth of our Clinical Trial Transparency and Clinical Trial Disclosure Services, below.

Clinical Trial Registration and Result Disclosures Services

MMS helps Sponsors achieve and surpass clinical trial disclosures reporting requirements for clinicaltrials.gov, the European Union Clinical Trials Register (EU-CTR), EU Clinical Trial Information System (EU-CTIS), and other international registries.

Our robust services, processes, and tools allow MMS to be your centralized transparency department with the ability to manage all workflow and clinical data reporting obligations for an entire pipeline.

Anonymization and Redaction of Documents

MMS is an innovator of risk-based clinical trial document anonymization, with industry thought leadership and the use of advanced AI tools to achieve both efficiency and quality in every deliverable. Internal anonymization processes and tools are designed to maximize data utility and protect patient privacy.

Anonymization of Data Sets

Our risk-based dataset anonymization approach protects patient privacy and maximizes the data utility by keeping the risk below our predetermined threshold, and our process is proven to produce high-quality anonymized datasets with less manual effort. The anonymization of each variable is driven by a standard rule set that can be reused across multiple studies.

Our rule-building technology allows MMS to switch rules based on the personal information in each variable. Our tool can anonymize individual patient level data in different data sources, including SAS transport files, SAS7BDAT, Excel, and CSV.

Plain Language Summaries of Clinical Trial Results for Laypersons

As an industry leader in the creation of lay summaries, MMS develops programs for Sponsors to meet and exceed current and future regulations. With a team of dedicated plain language summary writers, graphic designers, lay reviewers, and project managers, the transparency specialists at MMS are focused on ensuring the success of every plain language summary created.

Our global team enables quick mobilization, 24-hour support, and the ability to scale our services to meet your needs.

Suggested For You

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

perspectives

September 24th, 2024

Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry

perspectives

September 11th, 2024

From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

perspectives

September 4th, 2024

Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders

perspectives

August 27th, 2024

Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

perspectives

August 20th, 2024

Clinical Study Protocols: A Comprehensive Guide to Best Practices From A Senior Medical Writer